- Poster presentation
- Open Access
High Th17:Treg ratio may predict complete response to HDIL-2 in the setting of melanoma
© Diller et al. 2015
- Published: 4 November 2015
- Th17 Cell
- TREG Cell
- Paired Student
- Subsequent Cycle
In vitro and in vivo experiments have demonstrated a potent yet opposite effect of IL-2 on both regulatory T cells (TREG) and IL-17+CD45RA-CD4+ T cells (Th17). TREG cells have been implicated as an important immunoregulator enhancing tumor growth whereas Th17 cells may mediate tumor destruction. This study compares the effect of high-dose IL-2 (HDIL-2) on both the TREG and Th17 compartments in responders and non-responders.
Peripheral blood was collected at baseline and at 24, 48, 72, and 96 hours post-treatment from 6 patients undergoing HDIL-2 therapy under an IRB approved protocol. No patients enrolled received anti-PD-1 or anti-CTLA4 therapies. PBMCs were isolated and underwent intracellular cytokine and extracellular receptor staining for flow cytometry. Statistical analysis was performed using paired student's t tests via Prism 6.0e software.
Our results suggest a distinct immunophenotype indicative of response to HDIL-2. Analysis of peripheral TREG and Th17 cell frequencies early in the course of HDIL-2 therapy may help identify those patients who would benefit from subsequent cycles.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.